Pooled Platelet Lysate Production via Laser Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for canine osteoarthritis, such as platelet-rich plasma (PRP), are hindered by autologous nature and variability, necessitating a standardized, off-the-shelf, allogenic platelet-based product that can effectively mitigate clinical signs associated with inflammatory mediators like IL-1β and INF-γ.
Innovation Solution
A method involving the production of a pooled platelet lysate product using a pressurized rotating microfluidic filtration system, laser activation, and freeze/thaw cycles to create a highly pure, cell-free, and concentrated platelet lysate, which is then reconstituted and encapsulated for extended release, addressing the need for a standardized treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional PRP preparations are used for treating osteoarthritis, then the treatment can be provided, but the autologous nature and tremendous patient and processing variability hinder consistent effectiveness
Solution Approach 1:
The patent uses allogeneic platelet lysate as a standardized copy or substitute for autologous PRP, eliminating patient-specific variability while maintaining the therapeutic benefits of platelet-derived factors. The pooled platelet lysate product serves as a consistent, off-the-shelf alternative to customized patient-specific PRP preparations.
2Reliability
If platelet lysate preparations are used instead of traditional PRP, then immunogenicity concerns are reduced and storage is improved, but the need for complex processing steps remains
Solution Approach 1:
The patent performs preliminary actions during the platelet lysate preparation process, including pre-activation with laser irradiation and pre-freezing in controlled conditions. These preliminary steps ensure the product is pre-conditioned for stability and efficacy, reducing the need for complex post-processing or special handling requirements later.
3Quantity of substance
If laser activation is applied to concentrated PRP, then cytokine release is enhanced, but the risk of overheating and platelet damage increases
Solution Approach 1:
The patent applies periodic or pulsed laser irradiation to activate platelets, allowing intervals for heat dissipation between pulses. This periodic activation method enhances cytokine release through cumulative photostimulation while preventing thermal damage by allowing the sample to cool between laser pulses.
Solution Approach 2:
The patent replaces mechanical or chemical activation methods with laser (optical) activation. This substitution allows for precise control of activation energy delivery, enabling enhanced cytokine release through photostimulation without the thermal damage associated with conventional heating or mechanical stress methods.
4Quantity of substance
If multiple freeze/thaw cycles are performed on activated C-PRP, then platelet lysis is improved, but product degradation and loss of bioactivity may occur
Solution Approach 1:
The patent performs preliminary laser activation of platelets before the freeze/thaw cycles. This pre-activation step triggers intracellular changes and membrane permeabilization that facilitate more efficient and complete lysis during subsequent freezing, reducing the number of cycles needed and minimizing bioactivity loss.
Solution Approach 2:
The patent optimizes the parameters of freeze/thaw cycles, including temperature extremes, duration of each phase, and number of cycles. By carefully controlling these parameters and combining them with prior laser activation, the method achieves complete platelet lysis while preserving the bioactivity of released factors through optimized thermal stress conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting product demonstrates chondroprotective effects by suppressing inflammatory pathways and enhancing synoviocyte proliferation and hyaluronic acid production, providing a therapeutic option for canine osteoarthritis with improved stability and availability.
Implementation Method 1
separating platelets from the whole blood using a pressurized rotating microfluidic filtration system
Implementation Method 2
pressurized rotating microfluidic filtration system
Implementation Method 3
creating platelet rich plasma (PRP) by concentrating the platelets in plasma and removing red blood cells and white blood cells using centrifugation
Implementation Method 4
laser activating the C-PRP to create an activated C-PRP product
Implementation Method 5
freezing and thawing the activated C-PRP product at least 3 times, wherein vortexing is performed after each thaw
Data Source
AI summary
A method of creating a pooled platelet lysate product may include obtaining whole blood from a source; separating platelets from the whole blood using a pressurized rotating microfluidic filtration system; creating platelet rich plasma (PRP) by concentrating the platelets in plasma and removing red blood cells and white blood cells using centrifugation; centrifuging the PRP, removing the plasma, and re-suspending the PRP in the lactated ringers solution (LRS) to create concentrated PRP (C-PRP); laser activating the C-PRP to create an activated C-PRP product; freezing and thawing the activated C-PRP product at least 3 times, wherein vortexing and sonication are performed after each thaw; and reconstituting the activated C-PRP in a saline to create a platelet lysate product with a known potency.